VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma

Journal of Pathology

Volumn 196, Issue 2, 2002, Pages 186-193

  Schraml, Peter ^a,b   Struckmann, Kirsten ^a   Hatz, Florian ^a   Sonnet, Stefan ^a   Kully, Charlotte ^a   Gasser, Thomas ^a   Sauter, Guido ^a   Mihatsch, Michael J ^a   Moch, Holger ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Kantonsspital Liestal   (Switzerland)

Author keywords

Clinical outcome; Ki 67; Kidney; Microvessel density; Renal cell carcinoma; VHL mutation

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FRAMESHIFT MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LABELING INDEX; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); NONSENSE MUTATION; OPEN READING FRAME; PRIORITY JOURNAL; PROGNOSIS; SEQUENCE ANALYSIS; TUMOR CELL; TUMOR VASCULARIZATION;

ANALYSIS OF VARIANCE; CARCINOMA, RENAL CELL; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; KIDNEY NEOPLASMS; LIGASES; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; POLYMERASE CHAIN REACTION; PROGNOSIS; SEQUENCE ANALYSIS, DNA; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0036154040     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1034     Document Type: Article

References (42)

1. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer
2. Identification of the von Hippel-Lindau disease tumor suppressor gene
3. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: A Swiss experience with 588 tumors
4. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma
5. Mutations of the VHL tumour suppressor gene in renal carcinoma
6. The von Hippel-Lindau tumor suppressor gene
7. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene
8. Tumour suppression by the human von Hippel-Lindau gene product
9. Vascular permeability factor mRNA and protein expression in human kidney
10. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
11. Vascular endothelial growth factor expression is increased in renal cell carcinoma
12. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein
13. Future prognostic factors for renal cell carcinoma: Workgroup No. 5. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)
14. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma
15. The Heidelberg classification of renal cell tumours
16. Histopathology and classification of renal cell tumors (adenomas, oncocytomas, and carcinomas): The basic cytological and histopathological elements and their use for diagnostics
17. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
18. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma
19. Immunohistochemical and immunochemical characterization of a new endothelial cell-specific antigen
20. Intratumor microvessel density as a prognostic factor in cancer
21. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
22. A high frequency of sequence alterations is due to formalin fixation of archival specimens
23. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma
24. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas
25. VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation
26. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma
27. Novel somatic mutations in the VHL gene in Swedish archived sporadic renal cell carcinomas
28. Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene
29. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma
30. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix
31. Signaling by integrins: Implications for tumorigenesis
32. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity
33. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
34. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
35. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity
36. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways
37. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma
38. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma
39. Microvessel density in renal cell carcinoma: Lack of prognostic significance
40. Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis